Biotech Values

[dewophile]

To me it seems pretty objective that GSK's definition of severe disease is very similar to PFE's definition of standard LRTI
GSK doesn't break down how many of the sLRTI patients had 3 or more symptoms (PFE's definition of sLRTI)
PFE doesn't break down how many patients had LRTI with one or more symptoms of LRTI

The only efficacy endpoint that is defined exactly the same is ARI - which is symptom of respiratory tract infection (not limited to LOWER RTI) for one day or more and positive for RSV
GSK had efficacy of 71.7 on this measure we don't knwo PFE yet but that is the only true apples to apples, but there is plenty here to suggest the closest important metric to compare is the 67% vs 94% (I thinkt he numbers at least at interim are going to be too small to compare hospitalizations, deaths, etc)